ProCE Banner Activity

State of the Art Management in Relapsed/Refractory CLL

Slideset

Download these slides from our ASCO 2021 live satellite webinar on CLL to review the most current clinical data on treating patients with relapsed/refractory CLL.

Released: June 08, 2021

Expiration: June 07, 2022

Share

Faculty

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BeiGene, Ltd.

Lilly

Pharmacyclics LLC and Janssen

Faculty Disclosure

Primary Author

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and has received consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Johnson & Johnson, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.